Immunohistochemical Demonstration of Desmin in Canine Smooth Muscle Tumors

1987 ◽  
Vol 24 (3) ◽  
pp. 211-215 ◽  
Author(s):  
C. B. Andreasen ◽  
E. A. Mahaffey

Sections of formalin-fixed, paraffin-embedded canine leiomyomas, leiomyosarcomas, or fibrosarcomas were examined by immunohistochemical methods for the presence of desmin. Twenty-two leiomyomas and leiomyosarcomas were stained using the avidin-biotin complex technique, and 14 samples demonstrated positive staining for desmin. The eight negative results obtained may reflect differences in fixation or the affinity of the primary antibody for the tissues examined. Desmin was specific for myogenic tissues. Five canine fibrosarcomas examined immunohistochemically were all negative for desmin staining. The results indicate that desmin is a useful marker for immunohistochemical identification of canine leiomyomas and leiomyosarcomas.

2002 ◽  
Vol 39 (3) ◽  
pp. 311-321 ◽  
Author(s):  
K. F. Barnhart ◽  
J. Wojcieszyn ◽  
R. W. Storts

This study examined immunohistochemical staining patterns for several meningioma variants involving either the brain or spinal cord of dogs. Formalin-fixed, paraffin-embedded tissue from 15 tumors was obtained. The selected tumor group included seven meningothelial, three transitional, two malignant (anaplastic), one myxoid, one papillary, and one osteomatous meningiomas. Tumors were evaluated for reactivity to the following six immunohistochemical markers: vimentin, pancytokeratin, glial fibrillary acidic protein (GFAP), S100, neuron-specific enolase (NSE), and synaptophysin. Vimentin expression was detected in all meningiomas, and 14 of 15 tumors demonstrated intense vimentin staining in more than 50% of the neoplastic cells. Pancytokeratin expression was present in 11 of 15 neoplasms; however, positive staining frequently was focal and often involved a small percentage of the neoplastic cells. GFAP expression was detected in a single, anaplastic meningioma. Although expression of NSE and S100 was detected in 12 of 25 meningiomas, the intensity of the staining and the percentage of positive neoplastic cells was highly variable. Synaptophysin was uniformly negative. These results will help to establish immunohistochemical profiles for meningiomas that will improve our ability to correctly differentiate these neoplasms of meningeal origin from central nervous system tumors originating from other sites.


2002 ◽  
Vol 126 (2) ◽  
pp. 170-172 ◽  
Author(s):  
Timothy S. Loy ◽  
Roy W. Phillips ◽  
Chadwick L. Linder

Abstract Context.—The monoclonal antibody A103 recognizes an antigen on melanoma cells known as Melan-A or MART-1. Recent studies have shown that A103 also reacts with adrenal cortical cells and may be useful in the diagnosis of adrenal cortical tumors. However, only small numbers of some of the tumors in the differential diagnosis of adrenal cortical neoplasms have been studied. Objective.—To study the specificity of A103 immunohistochemistry in a large number of tumors in the differential diagnosis of adrenal cortical neoplasms. Design.—Formalin-fixed, paraffin-embedded tissue from 21 adrenal cortical tumors, 16 cases of metastatic carcinoma to the adrenal, 10 pheochromocytomas, and 269 extra-adrenal carcinomas was evaluated for A103 immunoreactivity using a commercially available antibody (Novocastra, Newcastle, UK). Results.—Positive staining was seen in all of the adrenal cortical tumors but in none of the adrenal metastases or pheochromocytomas. In the 269 extra-adrenal carcinomas, A103 immunoreactivity was limited to a single ovarian serous carcinoma. Conclusion.—A103 immunostaining is useful in distinguishing adrenal cortical neoplasms from other carcinomas and pheochromocytoma.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2623-2623
Author(s):  
Anjali V. Morales ◽  
Katie Seo ◽  
Daniel A. Arber ◽  
Sabine Kohler ◽  
Youn H. Kim ◽  
...  

Abstract Primary cutaneous B-cell lymphomas (PCBCL) are a diverse group of lymphomas that are limited to the skin at the time of diagnosis. Clonally rearranged immunoglobulin (Ig) genes are a key feature of B-cell malignancies. While PCR for Ig rearrangement is well-established and characterized in nodal malignancies, PCR investigations of Ig clonality in PCBCL have been unstandardized and extremely inconsistent. In this study, we analyzed 27 cases of PCBCL (22 cases of PCBCL diagnosed at initial presentation and 5 cases of atypical lymphoid infiltrates (ALI)) for Ig clonality using standardized BIOMED-2 PCR protocols (InVivoScribe Technologies, San Diego, CA). We defined lesions of ALI as those that were clinically suspicious for lymphoma, but could not be confirmed as lymphoma by morphologic and/or immunohistochemical methods. These patients were followed clinically where an eventual diagnosis of lymphoma was made by morphologic and/or immunohistochemical methods. Our primary objective was to evaluate the sensitivity and specificity of the BIOMED-2 method for detecting clonality in PCBCL, including cases initially diagnosed as ALI. Our secondary objective was to assess the role of clonality in the diagnosis of PCBCL. 47 biopsies from 27 cases of PCBCL (7 T1aN0M0, 4 T2aN0M0, 3 T2bN0M0, 3 T3aN0M0, and 10 T3bN0M0) were tested for IGH and IGK gene rearrangements and the (14;18) translocation using BIOMED-2 primers. Select cases from patients with multiple biopsies were further analyzed by sequencing to identify identical clones. We found a clone in 24/27 (89%) cases overall (10/11, 91% marginal zone lymphoma (MZL); 10/11, 91% follicle center lymphoma (FCL); and 4/5 ALI)). Among the 47 biopsies, a clone was detected in 35/47 (75%) cases (13/19, 68% MZL; 15/19, 79% FCL; and 7/9, 78% ALI). We found that clonal detection was improved in cases with multiple biopsies. The t(14;18) translocation was present in 3/11 FCL cases and 1/5 ALI cases, but not detected in any biopsy from MZL cases. Addition of IGK analysis to IGH analysis alone increased sensitivity of clonal detection from 57% to 75%. No clonality was detected in 9 cases of reactive cutaneous lymphoid hyperplasia. While our study is small, the initial results demonstrate that the BIOMED-2 protocol shows high sensitivity and specificity in clonality detection in PCBCL the (14;18) translocation is rare in PCBCL in general, but can be detected in a minority of cases of FCL adding IGK primers to the analysis for clonality may increase its sensitivity over detection of IGH rearrangements alone clonality detection may lead to earlier diagnosis of PCBCL in cases otherwise thought to be ALI multiple biopsies can lead to a more definitive diagnosis of PCBCL with increased likelihood of clonal detection and formalin-fixed paraffin embedded tissues can be used very effectively to establish clonality in PCBCL. To our knowledge, this is the first report of a standardized approach for the detection of clonality in PCBCL. We propose a new algorithm in the diagnosis of PCBCL, where clonality assays are implemented when a definitive diagnosis cannot be made on clinical, morphologic, and/or immunophenotypic grounds. This novel characterization of PCBCL using archival tissue and the BIOMED-2 assay is a powerful strategy for clonality assessment and validation of the diagnosis of PCBCL.


2014 ◽  
Vol 67 (12) ◽  
pp. 1084-1087 ◽  
Author(s):  
Güzin Surat ◽  
William A Wallace ◽  
Ian F Laurenson ◽  
Amie-Louise Seagar

AimsTo investigate the diagnostic accuracy of IS6110 real-time PCR for detection of Mycobacterium tuberculosis complex (MTBC) in DNA extracted from formalin-fixed paraffin embedded (FFPE) tissues using two different methods. In the absence of material submitted for tuberculosis (TB) culture, MTBC detection in FFPE tissue can be an important aid to diagnosis.MethodsWe collected 144 FFPE tissue blocks (lung and lymph node) for IS6110 real-time PCR. Two DNA extraction methods (QIAamp FFPE tissue kit and NucliSENS easyMAG) were assessed within a general laboratory setting. PCR results were compared with histology and culture.ResultsIn the histological MTBC and culture MTBC (TB-positive) groups, 72.4% were IS6110-positive and 27.6% negative. IS6110-negative results were obtained from 98%, 61.5% and 84% of the histologically MTBC-negative (TB-negative) group, histologically TB/no culture group and sarcoidosis group, respectively. Review of 19 IS6110-positive patients in the latter three groups showed that 15 had clinical TB. Thirteen of 15 (86.7%) IS6110-positive patients in the histological TB/no culture group and 2 of 4 (50%) IS6110-positive patients in the sarcoidosis group were clinically diagnosed with TB which highlights the difficulty of a pathological diagnosis.ConclusionsIS6110 real-time PCR using easyMAG extracted DNA is a moderately sensitive, specific and rapid method for MTBC detection in FFPE material, but must be interpreted in the overall clinical context. PCR results can be available in around 5 h from FFPE specimen receipt, with minimal hands-on time.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 540-540
Author(s):  
Javier Freire ◽  
Lucia Garcia-Berbel ◽  
Saioa Dominguez-Hormaetxe ◽  
Saray Pereda ◽  
Ana De Juan ◽  
...  

540 Background: Breast cancer is currently the most frequent tumor among women. Despite the huge progress achieved in its early diagnosis, there are still many unsolved clinical issues, being the diagnosis, prognosis and treatment of papillary diseases (and specifically intraductal papilloma), one of the highest challenges. Because of its unpredictable clinical behavior, treatment of intraductal papilloma has generated a great controversy. Even though considered as a benign lesion, it presents high rate of malignant recurrence. This is the reason why there are clinicians supporting a complete excision of the papillary lesion, while others support an only expectant follow up. Previous results of our group have suggested that pro-Collagen 11 alpha 1 (pro-COL11A1) expression in cancer associated fibroblasts (CAFs) correlates with an infiltrating phenotype in breast lesions. We have analyzed the correlation between the differential expression of pro-COL11A1 in intraductal papilloma and their risk of malignant recurrence. Methods: Immunohistochemistry of pro-COL11A1 (clone 1E8.33, ONCOMATRIX, Bilbao, SPAIN) was performed in formalin fixed, paraffin embedded Core Needle Biopsy samples of 51 patients with intraductal papilloma. All patients had a minimum follow-up of 5 years. Results: Twenty-three out of 51 cases showed positive staining for COL11A1. Nine patients out of the positive cases relapsed as infiltrating carcinoma, two as intraductal papilloma and the rest had not recurred after five years of follow up. Only one case out of the 28 negative cases relapsed as invasive carcinoma. There were significant differences (p=0.0013) when comparing staining of individuals with malignant recurrence versus non recurrence and benign relapse patients, with a sensitivity of 90% and specificity of 66%. Conclusions: These data suggest that COL11A1 expression in CAFs is a highly sensitive biomarker to predict malignant relapse of intraductal papilloma. The low specificity might be biased by the complete excision of this lesion as the routine treatment or by a short follow-up of the patients.


2008 ◽  
Vol 45 (6) ◽  
pp. 825-828 ◽  
Author(s):  
D. H. Thamm ◽  
E. J. Ehrhart ◽  
J. B. Charles ◽  
Y. A. Elce

The enzyme cyclooxygenase-2 (COX-2) is expressed in some tumor and stromal tissues, and catalyzes production of prostaglandins with growth stimulatory, antiapoptotic, proangiogenic, and immunosuppressive properties. Pharmacologic inhibition of COX-2 is associated with antitumor activity in various human and canine malignancies. The purpose of this study was to assess COX-2 expression in a series of equine sarcoids, melanomas, and squamous-cell carcinomas (SCC). COX-2 expression was assessed in formalin-fixed paraffin-embedded tissues from 14 sarcoids, 11 melanomas, and 37 SCC that represent various anatomic sites by using standard immunohistochemical methods. COX-2 was expressed in 2 of 14 sarcoids, 7 of 11 melanomas, and 32 of 37 SCC, 56% of which demonstrated moderate-to-strong immunoreactivity. There were no differences in expression between anatomic sites. In conclusion, most equine SCC and many melanomas appear to express COX-2 and thus could respond to COX-2 inhibitor therapy.


Sign in / Sign up

Export Citation Format

Share Document